Every 8-K that Aura Biosciences, Inc. (AURA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AURA filings page.
Aura Biosciences reported second-quarter 2026 results and a strategic refocus on ocular oncology centered on its lead candidate bel-sar. The Phase 3 CoMpass trial in early choroidal melanoma is fully enrolled with 108 patients, conducted under an FDA Special Protocol Assessment, with topline data expected in the second half of 2027. Interim data in non-muscle invasive bladder cancer showed an 81% objective response and 69% complete response at three months, with all treatment-related adverse events Grade 1, but this program is being deprioritized to concentrate resources on ocular oncology.
As of June 30, 2026, Aura held $323.8 million in cash, cash equivalents and marketable securities and expects its cash runway to extend into the first half of 2029. Research and development expenses rose to $30.7 million and general and administrative expenses to $17.3 million, driving a wider quarterly net loss of $45.6 million. The company is implementing an organizational realignment, including a workforce reduction of about 20% and estimated restructuring charges of $2.9–$3.2 million. Leadership changes include appointing Susan Abu‑Absi as Chief Operating Officer and naming an interim principal financial officer while the current Chief Financial and Business Officer transitions to a consulting role.
Aura Biosciences, Inc. held a Special Meeting of Stockholders on August 5, 2026, where stockholders approved two governance proposals. Common stock outstanding and entitled to vote totaled 103,436,416 shares as of June 12, 2026, with 89,490,726 shares represented in person or by proxy, constituting a quorum.
Stockholders approved an amendment to the Tenth Amended and Restated Certificate of Incorporation to increase authorized common stock from 150,000,000 to 500,000,000 shares, with 62,993,701 votes for and 26,496,186 against. They also approved Amendment No. 1 to the 2021 Stock Option and Incentive Plan, with 46,369,676 votes for and 27,372,773 against.
Aura Biosciences expanded its Board of Directors from six to seven members and appointed Jeremy Bender, Ph.D., M.B.A., as a Class II independent director effective July 7, 2026, with a term running through the 2029 annual stockholders’ meeting. He will also serve on the Compensation and Nominating and Corporate Governance Committees.
Under the company’s amended Non-Employee Director Compensation Policy, Dr. Bender receives an initial stock option for 60,000 shares and an initial restricted stock unit award for 30,000 shares, vesting in three equal annual installments. The policy provides a $40,000 annual board retainer for members, higher retainers for committee roles, and larger ongoing annual equity awards, subject to caps of $800,000 for initial grants and $400,000 for annual grants. The press release highlights his biotechnology leadership experience and Aura’s late-stage development of its lead candidate bel-sar for early choroidal melanoma.
Aura Biosciences, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Common stock entitled to vote totaled 64,199,778 shares, with 52,784,744 shares present or represented by proxy.
Stockholders elected David Johnson and Teresa Marie Bitetti as Class II directors to serve until the 2029 Annual Meeting, with Johnson receiving 34,542,193 votes for and Bitetti receiving 40,526,332 votes for. Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 52,752,601 votes for, 17,348 against and 14,795 abstentions, and no broker non-votes.
Aura Biosciences reported a net loss of $33.7 million for the quarter ended March 31, 2026, wider than $27.5 million a year earlier, as it increased investment in late- and early-stage trials. Research and development expenses rose to $28.0 million, and general and administrative costs grew to $6.9 million.
The company ended the quarter with $114.7 million in cash, cash equivalents and marketable securities, then completed an oversubscribed $299 million equity financing on May 5, 2026, generating $280.8 million in net proceeds and using about $39.0 million to repurchase shares from Matrix Capital. Aura now expects its cash resources to fund operations into the second half of 2028.
Clinically, the Phase 3 CoMpass trial of bel-sar in early choroidal melanoma is progressing toward enrollment completion by mid‑2026 with topline data anticipated in the second half of 2027, while additional studies in metastases to the choroid, ocular surface cancers and non‑muscle invasive bladder cancer advance. Natalie Holles has been appointed Chief Executive Officer and President, succeeding founder Elisabet de los Pinos.
Aura Biosciences, Inc. completed an underwritten public offering of 39,591,000 common shares and pre-funded warrants to purchase up to 3,800,000 shares, all sold by the company. The underwriters also exercised in full their option to buy an additional 6,508,650 shares.
The shares were priced at $6.00 each, while each pre-funded warrant was priced at $5.99999 with a $0.00001 exercise price and is exercisable immediately, subject to ownership caps between 4.99% and 19.99%. Aura Biosciences received approximately $280.8 million in net proceeds.
The company plans to use about $241.8 million to advance clinical programs, including early choroidal melanoma and registration-enabling activities for bel-sar, and for general corporate purposes. It intends to use approximately $39.0 million to repurchase 6,922,870 shares from Matrix Capital Management Master Fund, LP at $5.64 per share. Aura Biosciences believes these resources will fund operations and capital needs into the second half of 2028.
Aura Biosciences, Inc. entered into a Repurchase Agreement with Matrix Capital Management Master Fund to buy back up to 6,922,870 shares of its common stock in a privately negotiated transaction. The repurchase price per share will match the price at which underwriters purchase shares in the company’s separately announced underwritten equity offering, which was set at $5.64 per share.
The company plans to fund the repurchase using a portion of net proceeds from the equity offering that exceed $200 million, after underwriting discounts and commissions. Matrix held approximately 10.8% of Aura’s outstanding common stock as of April 15, 2026. The stock repurchase is subject to the successful closing of the equity offering and other conditions and may not occur. Aura also disclosed preliminary cash, cash equivalents and marketable securities of about $114.7 million as of March 31, 2026, which are unaudited and subject to final accounting.
Aura Biosciences, Inc. has appointed industry veteran Natalie Holles as Chief Executive Officer, President and Class I director effective April 30, 2026, succeeding founder Elisabet de los Pinos, Ph.D., who is stepping down but will provide consulting services through October 30, 2026.
Holles’ package includes a $700,000 base salary, a target bonus of 55% of salary, and inducement equity equal to about 3% of Aura’s common stock and pre-funded warrants, split among options, RSUs and performance-based RSUs. Aura reported that its Phase 3 CoMpass trial of belzupacap sarotalocan in early choroidal melanoma has enrolled 86 patients, with more than 25 additional patients scheduled or identified, and reiterated guidance for enrollment completion by mid-2026 and topline data in the second half of 2027. The company also terminated its at-the-market prospectus after selling 1,055,362 shares for gross proceeds of about $6.7 million.
Aura Biosciences reported full-year 2025 results and updated its oncology pipeline. The company is advancing bel-sar, a virus-like drug conjugate, across ocular and urologic cancers. Its global Phase 3 CoMpass trial in early choroidal melanoma is enrolling faster than expected, with enrollment now targeted for completion by mid-2026 and topline data expected in the second half of 2027. A Phase 1b/2 trial in non-muscle-invasive bladder cancer is on track, with initial three-month data anticipated mid-2026, and multiple proof-of-concept ocular oncology studies are expected to read out in 2026.
As of December 31, 2025, Aura held $144.2 million in cash, cash equivalents and marketable securities and believes this will fund operations into the first quarter of 2027. Research and development expenses were $90.3 million for 2025, up from $73.3 million in 2024, reflecting progress of the Phase 3 melanoma trial and higher personnel costs. General and administrative expenses were $22.5 million, slightly below 2024 levels.
Net loss for 2025 was $106.2 million compared with $86.9 million in 2024, and basic and diluted net loss per share was $1.76 versus $1.75. Weighted average shares outstanding increased to about 60.3 million, driven by equity issuance and compensation. Management highlights bel-sar’s potential as a first-in-class, organ-preserving therapy across early choroidal melanoma, bladder cancer and other solid tumor indications, supported by favorable early safety and efficacy signals and multiple regulatory designations.
Aura Biosciences announced its financial results for the quarter ended September 30, 2025, via a press release furnished as Exhibit 99.1. The company also updated its corporate presentation for investor and analyst meetings, filed as Exhibit 99.2. The press release is furnished under Item 2.02, while the presentation is filed under Item 8.01.
The materials include forward-looking statements covering development timelines, regulatory interactions, manufacturing, commercialization plans, market opportunities, and financing needs. The company notes an expected cash runway into the first half of 2027, with outcomes subject to clinical, regulatory, and operational risks described in its risk factor disclosures.
Aura Biosciences (AURA) furnished a press release announcing its financial results for the quarter ended June 30, 2025 and filed an updated corporate presentation as Exhibit 99.2. The press release is furnished and explicitly not deemed "filed" for purposes of Section 18 of the Exchange Act; the corporate presentation is filed for purposes of Section 18. The company identifies itself as an emerging growth company and notes its common stock trades on The Nasdaq Global Market.
The filing includes a broad cautionary statement of forward-looking items, covering R&D timing and costs, preclinical and clinical trials, manufacturing, third-party collaborations, commercialization, funding and regulatory approvals, market size, and an expected cash runway into the first half of 2027.
On 17 June 2025 Aura Biosciences, Inc. (Nasdaq: AURA) held its 2025 Annual Meeting of Stockholders, as reported in the Form 8-K filed 18 June 2025 under Item 5.07.
Participation: 38,863,371 common shares—or 77.3 % of the 50,268,758 shares entitled to vote—were present or represented by proxy.
Proposal 1 – Election of Class I Directors (terms through 2028)
- Elisabet de los Pinos, Ph.D.: 28,961,014 for; 985,262 withheld; 8,917,095 broker non-votes
- Giovanni Mariggi, Ph.D.: 29,179,073 for; 767,203 withheld; 8,917,095 broker non-votes
Both nominees were duly elected.
Proposal 2 – Ratification of Independent Auditor
- Ernst & Young LLP ratified for fiscal year ending 31 Dec 2025 with 38,623,566 for; 232,989 against; 6,816 abstentions; zero broker non-votes.
No additional matters were submitted. The filing contains no financial performance metrics, guidance, or transactional disclosures; therefore the event is considered routine corporate governance with limited immediate financial impact.